Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS G12V mutant antigen-specific TCR-T cells
- Development stage
- Unknown
- Lead developer
- Jinling Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KRAS G12V mutant antigen-specific TCR-T cells are an autologous T-cell receptor (TCR) engineered T-cell therapy designed to target the KRAS G12V mutation, a common driver in various malignancies, particularly pancreatic cancer. These cells are specifically engineered to recognize the KRAS G12V neoantigen presented by the HLA-A*11:01 major histocompatibility complex (MHC) class I molecule. Developed by Jinling Hospital Affiliated to Nanjing University (Eastern Theater General Hospital), this therapy aims to provide a precision immunotherapy option for patients with advanced pancreatic cancer who have progressed on standard treatments. The treatment involves the ex vivo expansion and modification of a patient's own T cells to express a TCR specific to the mutant KRAS peptide, which are then re-infused to selectively eliminate tumor cells expressing the mutation.
- Other names
- HLA-A*11:01-restricted KRAS G12V mutant antigen-specific TCR-T cells
02
Targets
KRAS G12V/HLA-A*11:01 (KRAS G12V Mutant Peptide-HLA-A*11:01 Complex)KRAS G12V-derived peptide presented by HLA-DPB1*03:01 or HLA-DPB1*14:01KRASG12V (KRAS G12V)
Beyond the preview
Go deeper on KRAS G12V mutant antigen-specific TCR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS G12V mutant antigen-specific TCR-T cells.